CA3218824A1 - Stapled peptides and methods thereof - Google Patents

Stapled peptides and methods thereof Download PDF

Info

Publication number
CA3218824A1
CA3218824A1 CA3218824A CA3218824A CA3218824A1 CA 3218824 A1 CA3218824 A1 CA 3218824A1 CA 3218824 A CA3218824 A CA 3218824A CA 3218824 A CA3218824 A CA 3218824A CA 3218824 A1 CA3218824 A1 CA 3218824A1
Authority
CA
Canada
Prior art keywords
agent
independently
group
amino acid
staple
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3218824A
Other languages
English (en)
French (fr)
Inventor
Brian Halbert WHITE
Daniel Seungduk LA
Lorenzo Josue Alfaro-Lopez
Paula Cristina Ortet
Sarah Isabelle CAPPUCCI
Zhi Li
John Hanney Mcgee
Martin Robert TREMBLAY
Gregory L. Verdine
Yaguang Si
Kevin LING
Peicheng Du
Jonathan Barry Hurov
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fog Pharmaceuticals Inc
Original Assignee
Fog Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fog Pharmaceuticals Inc filed Critical Fog Pharmaceuticals Inc
Publication of CA3218824A1 publication Critical patent/CA3218824A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • C07K7/56—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring the cyclisation not occurring through 2,4-diamino-butanoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1077—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of residues other than amino acids or peptide residues, e.g. sugars, polyols, fatty acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA3218824A 2021-06-08 2022-06-08 Stapled peptides and methods thereof Pending CA3218824A1 (en)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163208487P 2021-06-08 2021-06-08
US63/208,487 2021-06-08
US202163224834P 2021-07-22 2021-07-22
US63/224,834 2021-07-22
US202263303952P 2022-01-27 2022-01-27
US63/303,952 2022-01-27
PCT/US2022/032738 WO2022261257A1 (en) 2021-06-08 2022-06-08 Stapled peptides and methods thereof

Publications (1)

Publication Number Publication Date
CA3218824A1 true CA3218824A1 (en) 2022-12-15

Family

ID=84425507

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3218824A Pending CA3218824A1 (en) 2021-06-08 2022-06-08 Stapled peptides and methods thereof

Country Status (9)

Country Link
US (1) US20240360179A1 (https=)
EP (1) EP4355350A4 (https=)
JP (1) JP2024522368A (https=)
KR (1) KR20240031957A (https=)
BR (1) BR112023025528A2 (https=)
CA (1) CA3218824A1 (https=)
IL (1) IL308790A (https=)
MX (1) MX2023014679A (https=)
WO (1) WO2022261257A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2018329956A1 (en) 2017-09-07 2020-08-20 Fog Pharmaceuticals, Inc. Agents modulating beta-catenin functions and methods thereof
MX2021001943A (es) 2018-08-20 2021-07-15 Fog Pharmaceuticals Inc Colecciones de péptidos, agentes peptídicos y métodos de uso de los mismos.
WO2024130217A1 (en) * 2022-12-15 2024-06-20 Fog Pharmaceuticals, Inc. Stapled peptides and methods thereof
CN120529912A (zh) * 2022-12-15 2025-08-22 帕拉比利斯药物公司 订书钉化肽及其方法
WO2024130224A2 (en) * 2022-12-16 2024-06-20 Purdue Research Foundation Stapled peptides for sensitization of cancer to treatment
KR20260035134A (ko) * 2023-06-06 2026-03-12 파라빌리스 메디슨즈 인코포레이티드 스테이플화 펩티드 및 이의 방법
WO2025265097A1 (en) * 2024-06-20 2025-12-26 Parabilis Medicines, Inc. Stapled peptides and methods thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3549951A3 (en) * 2008-12-09 2019-11-20 Dana Farber Cancer Institute, Inc. Methods and compositions for specific modulation of mcl-1
WO2012040459A2 (en) * 2010-09-22 2012-03-29 President And Fellows Of Harvard College Beta-catenin targeting peptides and uses thereof
EP3391898A3 (en) * 2013-03-13 2019-02-13 President and Fellows of Harvard College Stapled and stitched polypeptides and uses thereof
WO2016085280A1 (ko) * 2014-11-28 2016-06-02 서울대학교산학협력단 세포 투과성 스테이플 펩타이드, 이의 제조방법 및 그 용도
US10011631B2 (en) * 2015-12-01 2018-07-03 The University Of Hong Kong Stapled helical peptides and methods of synthesis
AU2018329956A1 (en) * 2017-09-07 2020-08-20 Fog Pharmaceuticals, Inc. Agents modulating beta-catenin functions and methods thereof
CN117567639A (zh) * 2017-10-27 2024-02-20 俄亥俄州国家创新基金会 用于细胞内递送装订肽的多肽缀合物
MX2021001943A (es) * 2018-08-20 2021-07-15 Fog Pharmaceuticals Inc Colecciones de péptidos, agentes peptídicos y métodos de uso de los mismos.
AU2021314310A1 (en) * 2020-07-22 2023-03-16 Fog Pharmaceuticals, Inc. Stapled peptides and methods thereof

Also Published As

Publication number Publication date
US20240360179A1 (en) 2024-10-31
KR20240031957A (ko) 2024-03-08
IL308790A (en) 2024-01-01
BR112023025528A2 (pt) 2024-02-27
EP4355350A1 (en) 2024-04-24
WO2022261257A1 (en) 2022-12-15
MX2023014679A (es) 2024-01-15
JP2024522368A (ja) 2024-06-18
EP4355350A4 (en) 2025-10-01

Similar Documents

Publication Publication Date Title
CA3218824A1 (en) Stapled peptides and methods thereof
AU2024204726A1 (en) TYK2 inhibitors and uses thereof
CA3186681A1 (en) Stapled peptides and methods thereof
EP3578561A1 (en) Spiro compounds
JP6918378B2 (ja) ＣａＭＫＩＩ阻害剤及びその使用
CN105102450B (zh) 作为PERK抑制剂的N‑(2，3‑二氢‑1H‑吡咯并[2，3‑b]吡啶‑5‑基)‑4‑喹唑啉胺和N‑(2，3‑二氢‑1H‑吲哚‑5‑基)‑4‑喹唑啉胺衍生物
CN110291065A (zh) 一种新的异二氢吲哚衍生物、其药物组合物及应用
JP7428833B2 (ja) ヒストン脱アセチル化酵素６阻害剤としての１，３，４－オキサジアゾール誘導体化合物、およびそれを含む医薬組成物
JP6797923B2 (ja) Ａｌｋおよびｓｒｐｋ阻害剤ならびに使用方法
CA3083616A1 (en) Myst family histone acetyltransferase inhibitors
JP2025519029A (ja) ＰＩ３Ｋα阻害剤及びその使用方法
WO2017184658A1 (en) ACYL SULFONAMIDE NaV1.7 INHIBITORS
JP2021505132A (ja) 核酸結合光プローブおよびその使用
EP2382215B1 (fr) Dérivés de 2-pyridin-2-yl-pyrazol-3(2h)-one, leur préparation et leur application en thérapeutique
CN117769556A (zh) 嘧啶并环类衍生物及其制备方法和用途
CN116283918B (zh) 一种降解受体酪氨酸激酶的双功能化合物及其应用
CN104804001B9 (zh) 4-取代吡咯并[2,3-d]嘧啶化合物及其用途
CN119264065A (zh) 一类细胞程序性坏死抑制剂及其制备方法和用途
CN110054577B (zh) 一类含脲和硫脲结构的化合物、合成方法及其应用
CN109641909A (zh) 雷帕霉素信号通路抑制剂的机理靶标及其治疗应用
CA2694994C (fr) Derives de n-heteroaryl-carboxamides tricycliques, leur preparation et leur application en therapeutique
CN110256346A (zh) 具有brd4蛋白抑制作用的菲啶酮类化合物及制备方法和应用
CN113004284B (zh) 作为血浆激肽释放酶抑制剂的四环类化合物及其用途
KR100746939B1 (ko) 염증억제 활성을 가지는ｎ-[1'-치환술폰아미드-스파이로(2ｈ-1-벤조피란-2,4-피페리딘)-6-일]치환아민 유도체, 그의 약학적으로허용가능한 염, 그의 제조방법 및 그의 용도
EP4644374A1 (en) Naphthylamide compound, and preparation method therefor and use thereof

Legal Events

Date Code Title Description
R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R11-R103 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUEST RECEIVED

Effective date: 20241105

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20241105

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250530

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250530

R13 Change to the name of applicant or owner recorded

Free format text: ST27 STATUS EVENT CODE: A-1-1-R10-R13-R104 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CHANGE OF NAME REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20250618